<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835822</url>
  </required_header>
  <id_info>
    <org_study_id>BRAZ-03-003</org_study_id>
    <nct_id>NCT00835822</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency</brief_title>
  <official_title>Multicenter, Prospective, Randomized, Double-Blind Study to Assess the Therapeutic Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Statistika Consultoria Ltda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the therapeutic efficacy and safety of Venocur
      Triplex®, administered BID for 60 days in patients with Chronic Venous Insufficiency rated
      between CEAP 2 and 4, in comparison to a Placebo group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of the score of the CVI symptoms, based on symptoms as leg pains, cramps, fatigue, aching legs, heavy legs sensation, heat or burning sensation and paresthesia (tingling/numbness)</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of each CVI symptoms - leg pains, cramps, fatigue, aching legs, heavy legs sensation, heat or burning sensation and paresthesia (tingling/numbness);</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Assessment through the adverse events reports</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of edema in patients rated between CEAP 3 and 4, as compared to the Placebo group</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of the study drug on the patient's quality of life using questionnaires SF-36 and CVIQ</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The global clinical improvement of the patient with CVI, using the CGI (Clinical Global Impression) scale.</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Venous Insufficiency</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm treated with Investigational product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm treated with placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venocur Triplex®</intervention_name>
    <description>Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>ABT-401</other_name>
    <other_name>venopyronum</other_name>
    <other_name>Venocur Triplex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has confirmed his/her willingness to participate in the study, after being
             informed about all the aspects of the study that might be relevant for his/her
             decision to participate, and has signed and dated the informed consent form, as
             approved by the Institutional Review Board/ Ethics Committee (IRB/EC)

          -  Patients of both sexes, aged above 18 years and below 65 years

          -  Presence of uni- or bilateral varicose veins with CVI, in both sexes

          -  The patient's CVI is rated between functional classes CEAP 2 and 4

          -  Present at least one symptom of CVI prior to the study - leg pains, cramps, fatigue,
             heavy legs sensation.

        Exclusion Criteria:

          -  If female, the patient has circulatory disorders exclusively during the pre-menstrual
             period

          -  If the patient is pregnant or breastfeeding

          -  The patient has received anticoagulants less than 15 days before study start

          -  The patient has used steroids or anti-inflammatory drugs less than 8 days before study
             start

          -  The patient has received radio or chemotherapy less than 7 days before study start

          -  The patient has used diuretics, phlebotrophic and venoactive drugs over the past 8
             days before enrollment in the study

          -  The patient has used compression stockings less than 8 days before study start

          -  Trauma or surgical treatment over the past 30 days before study start

          -  Prior surgical treatment related to CVI (past 12 months for surgery and past 6 months
             for sclerotherapy)

          -  Immobilization of lower limbs over the past 6 months

          -  Known allergy to the product's ingredients

          -  Presence of chronic inflammatory diseases (rheumatoid arthritis, for instance), severe
             chronic infectious diseases (AIDS, tuberculosis, hanseniasis, etc.)

          -  The patient has suffered from phlebitis or deep venous thrombosis in the past 6 months
             before the study

          -  Fibrous lymphedema, primary or secondary lymphedema and lipoedema;

          -  Concomitant erysipelas

          -  Active fungal infections of the lower limbs

          -  Peripheral arteries disease, cerebrovascular or coronary disease

          -  Severe systemic conditions (heart failure, liver, pulmonary or kidney failure, active
             neoplastic disease, severe arterial hypertension, uncontrolled diabetes, among
             others), over the past 6 months before study start

          -  Hematocrit: &lt; 32.0 mL RBC/dL for women and &lt; 36.0 mL RBC/dL for men

          -  Hemoglobin: &lt; 11.0 mL g/dL for women and &lt; 12.0 mL g/dL for men;

          -  Total protein and fractions: Total protein &lt; 6.4 g/dL, Albumin &lt; 4.0 g/dL, Globulin &lt;
             1g/dL and Albumin/Globulin &lt; 0.9%

          -  Serum creatinine: &gt; 1.0 mg/dL for women and &gt; 1.2 mg/dL for men or if patient in
             dialysis

          -  Aminotranferases (SGOT/AST and/or SGPT/ALT) more than twice the upper normal limit

          -  Participation in study with similar objectives over the past 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marilia</city>
        <state>Sao Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <last_update_submitted>February 3, 2009</last_update_submitted>
  <last_update_submitted_qc>February 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Suely Kumagai Inoue</name_title>
    <organization>Abbott Laboratórios do Brasil Ltda.</organization>
  </responsible_party>
  <keyword>Chronic Venous Insufficiency, Venocur Triplex®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

